Amikacin (BAY416651): Mechanisms and Benchmarks in Resistance Research

Executive Summary: Amikacin (BAY416651) is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A, with a molecular weight of 585.6 and formula C₂₂H₄₃N₅O₁₃. It exerts bactericidal effects by irreversibly binding to bacterial 30S ribosomal subunits, inhibiting protein synthesis (APExBIO product information). Amikacin demonstrates notable resistance to several aminoglycoside-modifying enzymes, although it is susceptible to acetylation by AAC (6')-I type enzymes. Recent clinical surveillance in Guangdong, China, highlights its application in research on carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae (Chen et al., 2025). The compound is water soluble at ≥5.86 mg/mL, optimally stored at -20°C, and intended strictly for research use. This article contextualizes Amikacin’s mechanistic profile and benchmarks its utility against emerging antibiotic resistance challenges.

Biological Rationale

Antibiotic resistance, particularly among Gram-negative pathogens, remains a critical threat to global health. The rise of carbapenem-resistant Enterobacteriaceae, including Enterobacter cloacae and Klebsiella pneumoniae, underscores the need for antibiotics that maintain efficacy against multidrug-resistant (MDR) strains. Aminoglycosides, such as Amikacin (BAY416651), are essential in this context due to their unique mode of action and partial resilience to common resistance mechanisms (see: Carbapenemase Gene Transmission in CREC). This research landscape demands molecular tools with well-characterized enzyme resistance, stability, and reproducibility in laboratory workflows.

Mechanism of Action of Amikacin (BAY416651) Aminoglycoside Antibiotic

Amikacin selectively binds to the 30S subunit of bacterial ribosomes, leading to misreading of mRNA and inhibition of protein synthesis. This action is bactericidal, resulting in cell death. Compared to other aminoglycosides, Amikacin is structurally modified to evade many aminoglycoside-modifying enzymes, including most acetyltransferases, nucleotidyltransferases, and phosphotransferases (APExBIO). However, AAC (6')-I type enzymes can acetylate Amikacin, conferring resistance in certain bacterial strains. This resistance mechanism is particularly relevant in studies of MDR Enterobacter cloacae and Klebsiella pneumoniae (see: Precision Antibiotic Tool for Multidrug Resistance Research), where gene transfer events can rapidly disseminate resistance determinants.

Evidence & Benchmarks

• In a 2022–2024 clinical study, 85.19% of carbapenem-resistant Enterobacter cloacae isolates harbored carbapenemase-encoding genes (CEGs), with 33.33% carrying blaNDM−1 on both chromosomes and plasmids (Chen et al., 2025).
• Amikacin retains bactericidal activity against many MDR strains due to its resistance to most aminoglycoside-modifying enzymes (APExBIO).
• The broth microdilution method confirmed higher resistance rates to alternative antibiotics (imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, levofloxacin) in CEG-positive strains versus CEG-negative strains (Chen et al., 2025).
• Plasmid conjugation experiments demonstrated a 95.65% success rate for transfer of CEGs, underpinning the importance of studying Amikacin resistance dynamics (Chen et al., 2025).
• Amikacin is insoluble in ethanol and DMSO but dissolves in water at ≥5.86 mg/mL; solutions should be prepared fresh or warmed to 37°C for 10 minutes for higher concentrations (product information).

This article extends prior coverage by integrating recent clinical molecular epidemiology with physicochemical and workflow benchmarks, clarifying the distinct roles of resistance gene carriage and antibiotic stability (see: Advanced Workflows for Antibiotic R...).

Applications, Limits & Misconceptions

Amikacin (BAY416651) is integral to in vitro and in vivo research on antibiotic resistance mechanisms, especially for carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae. Its robust enzyme resistance profile makes it valuable for screening and mechanistic studies, including evaluating the impact of aminoglycoside acetyltransferase AAC (6')-I mediated resistance. APExBIO provides Amikacin strictly for scientific research, not for clinical or diagnostic use (APExBIO product information).

Common Pitfalls or Misconceptions

• Amikacin is not universally effective against all aminoglycoside-resistant strains; AAC (6')-I enzymes can confer resistance.
• Long-term storage of Amikacin solutions is not recommended due to diminished stability.
• The compound is insoluble in organic solvents such as ethanol and DMSO; water is required for dissolution.
• Research use only: Amikacin from APExBIO is not intended for clinical therapeutic applications.
• Bacterial resistance can still emerge through gene transfer, even with Amikacin’s partial enzyme resistance (Chen et al., 2025).

Workflow Integration & Parameters

Amikacin (BAY416651) integrates into resistance research workflows via standardized protocols for bacterial culture and resistance gene transfer studies. For optimal results, researchers should align handling and storage with manufacturer guidance.

Protocol Parameters

• Solubility: Dissolve Amikacin in sterile water at concentrations ≥5.86 mg/mL; do not use DMSO or ethanol as solvents (product info).
• Stock Preparation: For concentrations above 5.86 mg/mL, gently warm to 37°C for 10 min or apply ultrasonic shaking.
• Storage: Store dry powder at -20°C. Use prepared solutions promptly; avoid long-term storage.
• Shipping: Ship on blue ice for small molecule integrity.
• Resistance Studies: Employ in broth microdilution assays for MDR Enterobacter cloacae and Klebsiella pneumoniae (Chen et al., 2025).

This protocol guidance updates and clarifies experimental troubleshooting strategies previously discussed in Applied Workflows in Resistance Research, with specific attention to solution stability and solvent selection.

Conclusion & Outlook

Amikacin (BAY416651) exemplifies the next generation of aminoglycoside antibiotics for research into MDR Enterobacter cloacae and Klebsiella pneumoniae. Its structural resistance to most modifying enzymes, coupled with clear handling protocols, supports robust experimentation on antibiotic resistance mechanisms. However, persistent risks of resistance emergence—especially via AAC (6')-I enzymes and mobile gene transfer—necessitate ongoing surveillance and mechanistic study. The recent molecular epidemiology from Guangdong hospitals underscores the importance of precise, reproducible antibiotic research tools. As workflows continue to evolve, integrating Amikacin with advanced genetic and phenotypic assays will remain critical for antibiotic resistance research (see: Applied Workflows in Antibiotic Resistance Research).